HEALTHWAY MEDICAL CORPORATION LIMITED
(Company Registration Number: 200708625C**)**
(Incorporated in the Republic of Singapore)

PROPOSED ISSUANCE OF NOTES – CONVERSION OF T2 CN B

---

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the announcements dated 17 January 2017, 19 January 2017, 6 February 2017, 13 February 2017, 24 February 2017, 11 March 2017, 23 March 2017, 24 March 2017, 28 March 2017, 31 March 2017, 4 April 2017, 11 April 2017, 12 April 2017, 13 April 2017, 21 April 2017 and 24 April 2017 (collectively "**Notes Announcements**") and the circular to Shareholders dated 6 April 2017 ("**Circular**").*

The Board of Directors ("**Board**") of Healthway Medical Corporation Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the Notes Announcements and the Circular regarding, *inter alia*, the issuance of T2 CN B for a principal amount of $60 million on 21 April 2017, the Transfer of T2 CN B and the service of notice by the Offeror on the Company to convert S$15 million worth of T2 CN B into 443,262,411 T2 CN B Conversion Shares.

The Board wishes to update Shareholders that the Company has today allotted and issued 443,262,411 T2 CN B Conversion Shares to the Offeror and the total number of issued Shares has increased from 2,755,742,456 Shares to 3,199,004,867 Shares.

The T2 CN B Conversion Shares shall rank *pari passu* in all respects with and carry all rights similar to the existing Shares, save that they will not rank for any dividends, rights, allotments or other distributions, the record date for which precedes the date of issue of the T2 CN B Conversion Shares.

Following the aforesaid conversion, there is S$45 million T2 CN B outstanding, convertible into 1,329,787,234 new Shares.

Responsibility Statement

The Directors of the Company (including those who have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this announcement are fair and accurate, and that there are no material facts not contained in this announcement, the omission of which would make any statement in this announcement misleading, and they jointly and severally accept responsibility accordingly.

Where any information has been extracted or reproduced from published or otherwise publicly available sources, the sole responsibility of the Directors of the Company has been to ensure through reasonable enquiries that such information is accurately extracted from such sources or, as the case may be, accurately reflected or reproduced in this announcement.

BY ORDER OF THE BOARD

Veronica Chan Wee Ping
President
25 April 2017

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.